Evaluating the Effect of Melatonin on Positive and Negative Symptoms of Schizophrenic Patients: A Randomized Placebo-Controlled Study
Objective: Schizophrenia is known as a severe psychiatric disorder with a broad range of clinical indications and symptoms such as positive and negative symptoms. This study was conducted with the aim of investigating the effect of melatonin on positive and negative symptoms of inpatients with schizophrenia.
Method: This study was conducted as a randomized placebo-controlled trial (double-blind) in the population of patients with schizophrenia. Study samples were selected from inpatients with schizophrenia, according to the DSM-5 criteria, who had not been diagnosed with a depressive episode of schizophrenia based on the Calgary questionnaire and who also met the inclusion criteria. 46 patients with schizophrenia were randomly assigned to the intervention (6 mg melatonin per day as two 3 mg pills for six weeks) and placebo groups. The positive and negative symptom scale (PANSS) was used to assess the effect of treatment at T1 (before intervention), T2 (three weeks after beginning the intervention) and T3 (six weeks after beginning the intervention). To check the research hypotheses, multiple comparison statistics were used by the SPSS 22 software.
Results: The placebo and melatonin groups had no significant difference in terms of PANSS scores (negative, positive, general and total symptom scores) at T1. Also, there was no difference in PANSS scores between the two groups at T2. However, at T3, there was a significant difference between the two groups only in the score of negative symptoms of PANSS (P = 0.036), so that negative symptoms of schizophrenia were significantly reduced in the intervention group compared to the placebo group. Furthermore, based on within-group analyzes, all PANSS scores were significantly reduced in the two groups at T2 and T3 (P < 0.05).
Conclusion: Long-term use (at least six weeks) of melatonin can improve the negative symptoms of schizophrenia. Since antipsychotics can better affect the positive symptoms, the use of melatonin in combination with these drugs may perhaps further improve the patients’ symptoms.
2. Alavi SS, Mohammadi MR, Hooshyari Z, Mohammadi Kalhori S, Salehi M, Salmanian M, et al. Epidemiology of Psychotic Disorders Based on Demographic Variables in Iranian Children and Adolescents. Iran J Psychiatry. 2021;16(1):1-12.
3. Mongan D, Ramesar M, Föcking M, Cannon M, Cotter D. Role of inflammation in the pathogenesis of schizophrenia: A review of the evidence, proposed mechanisms and implications for treatment. Early Interv Psychiatry. 2020;14(4):385-97.
4. Khaleghi A, Mohammadi MR, Shahi K, Nasrabadi AM. Computational Neuroscience Approach to Psychiatry: A Review on Theory-driven Approaches. Clin Psychopharmacol Neurosci. 2022;20(1):26-36.
5. Häfner H. From Onset and Prodromal Stage to a Life-Long Course of Schizophrenia and Its Symptom Dimensions: How Sex, Age, and Other Risk Factors Influence Incidence and Course of Illness. Psychiatry J. 2019;2019:9804836.
6. Khaleghi A, Mohammadi MR, Zandifar A, Ahmadi N, Alavi SS, Ahmadi A, et al. Epidemiology of psychiatric disorders in children and adolescents; in Tehran, 2017. Asian J Psychiatr. 2018;37:146-53.
7. Talepasand S, Mohammadi MR, Alavi SS, Khaleghi A, Sajedi Z, Akbari P, et al. Psychiatric disorders in children and adolescents: Prevalence and sociodemographic correlates in Semnan Province in Iran. Asian J Psychiatr. 2019;40:9-14.
8. Nefzi R, Larnaout A, Ammar HB, Khelifa E, Aissa A, El Hechmi Z. S200. HYPOVITAMINOSIS D IN SCHIZOPHRENIA: PREVALENCE AND ASSOCIATED CLINICAL CHARACTERISTICS. Schizophr. Bull. 2018;44(Suppl 1):S403-S.
9. Barlati S, Deste G, Gregorelli M, Vita A. Autistic traits in a sample of adult patients with schizophrenia: prevalence and correlates. Psychol Med. 2019;49(1):140-8.
10. Cohen CI, Freeman K, Ghoneim D, Vengassery A, Ghezelaiagh B, Reinhardt MM. Advances in the Conceptualization and Study of Schizophrenia in Later Life: 2020 Update. Clin Geriatr Med. 2020;36(2):221-36.
11. Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P t. 2014;39(9):638-45.
12. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-23.
13. Yang YS, Marder SR, Green MF. Repurposing Drugs for Cognition in Schizophrenia. Clin Pharmacol Ther. 2017;101(2):191-3.
14. Goff DC. The Pharmacologic Treatment of Schizophrenia-2021. Jama. 2021;325(2):175-6.
15. Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64-77.
16. Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis. 2012;27(2):113-9.
17. Morera-Fumero AL, Abreu-Gonzalez P. Role of melatonin in schizophrenia. Int J Mol Sci. 2013;14(5):9037-50.
18. Bastos MAV, Jr., Oliveira Bastos PRH, Portella RB, Soares LFG, Conde RB, Rodrigues PMF, Jr., et al. Pineal gland and schizophrenia: A systematic review and meta-analysis. Psychoneuroendocrinology. 2019;104:100-14.
19. Simek J. Schizophrenia, Mental Disintegration, and Melatonin. Act. Nerv. Super. 2018;60(3):86-9.
20. Monti JM, Monti D. Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Med Rev. 2004;8(2):133-48.
21. Baandrup L, Fagerlund B, Glenthoj B. Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo. Eur Arch Psychiatry Clin Neurosci. 2017;267(2):163-71.
22. Duan C, Jenkins ZM, Castle D. Therapeutic use of melatonin in schizophrenia: A systematic review. World J Psychiatry. 2021;11(8):463-76.
23. Miola A, Fornaro M, Sambataro F, Solmi M. Melatonin and melatonin-agonists for metabolic syndrome components in patients treated with antipsychotics: A systematic review and meta-analysis. Hum Psychopharmacol. 2022;37(2):e2821.
24. Edition F. Diagnostic and statistical manual of mental disorders. Am Psychiatric Assoc. 2013;21(21):591-643.
25. Rostami R, Kazemi R, Khodaie-Ardakani MR, Sohrabi L, Ghiasi S, Sadat Kamali Z, et al. The Persian version of the Calgary Depression Scale for Schizophrenia (CDSS-P). Asian J Psychiatr. 2019;45:44-9.
26. Modabbernia A, Heidari P, Soleimani R, Sobhani A, Roshan ZA, Taslimi S, et al. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study. J Psychiatr Res. 2014;53:133-40.
27. Shirayama Y, Takahashi M, Suzuki M, Tsuruoka Y, Sato K. Effects of Add-on Ramelteon on Cognitive Impairment in Patients with Schizophrenia: An Open-label Pilot Trial. Clin Psychopharmacol Neurosci. 2014;12(3):215-7.
28. Ghamari GH, Molavi P, Heshmati R. Exploration of the factor structure of positive and negative syndrome scale in schizophrenia spectrum disorders. J. Clin. Psychol. 2010:10-1.
29. Andrabi SS, Vishnoi S, Kaushik M, Parveen K, Tabassum H, Akram M, et al. Reversal of Schizophrenia-like Symptoms and Cholinergic Alterations by Melatonin. Arch Med Res. 2019;50(5):295-303.
30. Okusaga OO. Accelerated aging in schizophrenia patients: the potential role of oxidative stress. Aging Dis. 2014;5(4):256-62.
31. Naguy A. Therapeutic use of melatonin in schizophrenia-more than meets the eye! World J Psychiatry. 2022;12(3):533-5.
32. Lushington K, Pollard K, Lack L, Kennaway DJ, Dawson D. Daytime melatonin administration in elderly good and poor sleepers: effects on core body temperature and sleep latency. Sleep. 1997;20(12):1135-44.
33. Kayumov L, Brown G, Jindal R, Buttoo K, Shapiro CM. A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosom Med. 2001;63(1):40-8.
34. Gobbi G, Comai S. Differential Function of Melatonin MT(1) and MT(2) Receptors in REM and NREM Sleep. Front Endocrinol (Lausanne). 2019;10:87.
35. Trbovic SM. Schizophrenia as a possible dysfunction of the suprachiasmatic nucleus. Med Hypotheses. 2010;74(1):127-31.
36. Ashton A, Jagannath A. Disrupted Sleep and Circadian Rhythms in Schizophrenia and Their Interaction With Dopamine Signaling. Front Neurosci. 2020;14:636.
37. Hardman S, O'Mahony E. Is there a role for melatonin in the treatment of schizophrenia? Prog. Neurol. Psychiatry. 2022;26(3):16-9.
|Issue||Vol 18 No 2 (2023)|
|Melatonin Randomized Controlled Trial Schizophrenia Signs and Symptoms|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|